Christine A Iacobuzio-Donahue

List of Articles by Year
in descending order

218 PR articles	37,391 PR citations	3939 86 PR h-index	3569 187 g-index
242 documents	47469 doc citations	3842 93 h-index	78812 citing authors

#	Article	IF	Citations
1	The Evolutionary Forest of Pancreatic Cancer. Cancer Discovery, 2025, 15, 329-345.	25.1	14
2	Role of clonal inflammatory microglia in histiocytosis-associated neurodegeneration. Neuron, 2025, 113, 1065-1081.e13.	11.0	5
3	Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across disease stages. Cancer Research, 2024, 84, C074-C074.	3.8	0
4	The nuclear factor ID3 endows macrophages with a potent anti-tumour activity. Nature, 2024, 626, 864-873.	37.9	52
5	A microglia clonal inflammatory disorder in Alzheimerâ€™s disease. ELife, 2024, 13, .	1.6	4
6	Mapping the tumor stress network reveals dynamic shifts in the stromal oxidative stress response. Cell Reports, 2024, 43, 114236.	6.3	28
7	A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome Classifier. Clinical Cancer Research, 2024, 30, 3499-3511.	6.8	7
8	A Targetable Secreted Neural Protein Drives Pancreatic Cancer Metastatic Colonization and HIF1Î± Nuclear Retention. Cancer Discovery, 2024, 14, 2489-2508.	25.1	9
9	Islands of genomic stability in the face of genetically unstable metastatic cancer. PLoS ONE, 2024, 19, e0298490.	2.3	2
10	Application of high-throughput single-nucleus DNA sequencing in pancreatic cancer. Nature Communications, 2023, 14, .	13.7	24
11	Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2023, 29, 1368-1374.	6.8	19
12	Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms. Clinical Epigenetics, 2023, 15, .	3.9	6
13	STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma. Nature, 2023, 616, 806-813.	37.9	180
14	Clonal evolution during metastatic spread in high-risk neuroblastoma. Nature Genetics, 2023, 55, 1022-1033.	25.2	42
15	Tissue-specific features of the T cell repertoire after allogeneic hematopoietic cell transplantation in human and mouse. Science Translational Medicine, 2023, 15, .	12.5	15
16	The Ratio of Key Metabolic Transcripts Is a Predictive Biomarker of Breast Cancer Metastasis to the Lung. Cancer Research, 2023, 83, 3478-3491.	3.8	12
17	Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma. Cancer Research, 2023, 83, 3796-3812.	3.8	17
18	MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Cancer Discovery, 2022, 12, 542-561.	25.1	91

#	Article	IF	Citations
19	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	33.7	524
20	Genomic and transcriptomic analysis of a library of small cell lung cancer patient-derived xenografts. Nature Communications, 2022, 13, .	13.7	44
21	Evidence for reduced BRCA2 functional activity in Homo sapiens after divergence from the chimpanzee-human last common ancestor. Cell Reports, 2022, 39, 110771.	6.3	8
22	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature, 2022, 606, 389-395.	37.9	169
23	Concurrent GermlineBRCA1/2and Mismatch Repair Mutations in Young-Onset Pancreatic and Colorectal Cancer: The Importance of Comprehensive Germline and Somatic Characterization to Inform Therapeutic Options. JCO Precision Oncology, 2022, , .	1.9	4
24	Systematic comparison of pancreatic ductal adenocarcinoma models identifies a conserved highly plastic basal cell state. Cancer Research, 2022, , .	3.8	8
25	Ordered and deterministic cancer genome evolution after p53 loss. Nature, 2022, 608, 795-802.	37.9	200
26	Clinico-genomic Characterization ofATMand HRD in Pancreas Cancer: Application for Practice. Clinical Cancer Research, 2022, 28, 4782-4792.	6.8	27
27	BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling. Nature Communications, 2022, 13, .	13.7	57
28	MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nature Cancer, 2022, 3, 1367-1385.	22.5	95
29	Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology, 2021, 160, 362-377.e13.	0.9	142
30	Inflammatory Leptomeningeal Cytokines Mediate COVID-19 Neurologic Symptoms in Cancer Patients. Cancer Cell, 2021, 39, 276-283.e3.	33.0	68
31	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Clinical Cancer Research, 2021, 27, 2111-2118.	6.8	10
32	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. Journal of the National Cancer Institute, 2021, 113, 1194-1202.	4.6	53
33	Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma. BMC Cancer, 2021, 21, .	2.9	29
34	Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Nature Communications, 2021, 12, .	13.7	30
35	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. Cancer Discovery, 2021, 11, 3028-3047.	25.1	148
36	The pancreatic cancer genome revisited. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 469-481.	45.8	175

#	Article	IF	Citations
37	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	4.0	38
38	The mutational landscape of human somatic and germline cells. Nature, 2021, 597, 381-386.	37.9	337
39	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical Cancer Research, 2021, 27, 1516-1525.	6.8	12
40	Methylation-based Cell-free DNA Signature for Early Detection of Pancreatic Cancer. Pancreas, 2021, 50, 1267-1273.	0.9	29
41	ID1 Mediates Escape from TGFÎ² Tumor Suppression in Pancreatic Cancer. Cancer Discovery, 2020, 10, 142-157.	25.1	74
42	A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma. Nature Cancer, 2020, 1, 59-74.	22.5	181
43	Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science, 2020, 369, 276-282.	36.2	255
44	Accelerated single cell seeding in relapsed multiple myeloma. Nature Communications, 2020, 11, .	13.7	64
45	Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 30670-30678.	7.5	23
46	Pancreatic cancers suppress negative feedback of glucose transport to reprogram chromatin for metastasis. Nature Communications, 2020, 11, .	13.7	28
47	HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Reports, 2020, 31, 107625.	6.3	116
48	Simple mucinous cysts of the pancreas have heterogeneous somatic mutations. Human Pathology, 2020, 101, 1-9.	2.3	17
49	Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. Cell, 2020, 181, 1643-1660.e17.	33.7	872
50	Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer, 2020, 126, 3939-3949.	4.0	66
51	The Evolutionary Origins of Recurrent Pancreatic Cancer. Cancer Discovery, 2020, 10, 792-805.	25.1	97
52	Pan-cancer analysis of whole genomes. Nature, 2020, 578, 82-93.	37.9	2,826
53	Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. Modern Pathology, 2020, 33, 1822-1831.	4.8	54
54	The mutational landscape of normal human endometrial epithelium. Nature, 2020, 580, 640-646.	37.9	445

#	Article	IF	Citations
55	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. Cancer Research, 2020, 80, 1681-1692.	3.8	46
56	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research, 2020, 26, 3239-3247.	6.8	199
57	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. Journal of Clinical Investigation, 2020, 130, 6668-6676.	10.6	42
58	CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Abdominal Radiology, 2019, 44, 3148-3157.	1.7	48
59	An analysis of genetic heterogeneity in untreated cancers. Nature Reviews Cancer, 2019, 19, 639-650.	60.8	192
60	Cancer biology as revealed by the research autopsy. Nature Reviews Cancer, 2019, 19, 686-697.	60.8	75
61	Cell division rates decrease with age, providing a potential explanation for the age-dependent deceleration in cancer incidence. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20482-20488.	7.5	82
62	Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clinical Epigenetics, 2019, 11, .	3.9	146
63	Characterization of genetic subclonal evolution in pancreatic cancer mouse models. Nature Communications, 2019, 10, .	13.7	23
64	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	25.1	140
65	Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer, 2019, 125, 1441-1448.	4.0	39
66	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	4.6	211
67	Unifying cancer and normal RNA sequencing data from different sources. Scientific Data, 2018, 5, .	5.7	209
68	Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas, 2018, 47, 208-212.	0.9	32
69	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	6.8	338
70	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	33.0	863
71	Precancerous neoplastic cells can move through the pancreatic ductal system. Nature, 2018, 561, 201-205.	37.9	119
72	Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science, 2018, 360, .	36.2	237

#	Article	IF	Citations
73	Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discovery, 2018, 8, 1112-1129.	25.1	951
74	Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology, 2018, 155, 668-673.	0.9	112
75	Reconstructing metastatic seeding patterns of human cancers. Nature Communications, 2017, 8, .	13.7	135
76	Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nature Genetics, 2017, 49, 367-376.	25.2	445
77	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nature Genetics, 2017, 49, 358-366.	25.2	382
78	Transcriptional Mechanisms of Resistance to Antiâ€“PD-1 Therapy. Clinical Cancer Research, 2017, 23, 3168-3180.	6.8	76
79	Alterations of type II classical cadherin, cadherinâ€10 (CDH10), is associated with pancreatic ductal adenocarcinomas. Genes Chromosomes and Cancer, 2017, 56, 427-435.	3.0	11
80	Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling. Cancer Research, 2017, 77, 3325-3335.	3.8	12
81	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research, 2017, 23, 6094-6100.	6.8	192
82	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	37.9	1,065
83	An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course. Journal of Physical Education and Sports Management, 2017, 3, a001701.	1.4	7
84	Hypermutation In Pancreatic Cancer. Gastroenterology, 2017, 152, 68-74.e2.	0.9	199
85	Mutant p53 Together with TGFÎ² Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clinical Cancer Research, 2017, 23, 1607-1620.	6.8	43
86	Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing. Annals of Surgery, 2016, 263, 153-161.	4.6	53
87	ETS-Transcription Factor ETV1 Regulates Stromal Expansion andÂMetastasis in Pancreatic Cancer. Gastroenterology, 2016, 151, 540-553.e14.	0.9	54
88	Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Annals of Surgery, 2016, 264, 1073-1081.	4.6	143
89	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. Cancer Research, 2016, 76, 3351-3363.	3.8	36
90	TGF-Î² Tumor Suppression through a Lethal EMT. Cell, 2016, 164, 1015-1030.	33.7	574

#	Article	IF	Citations
91	Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nature Medicine, 2016, 22, 497-505.	33.0	551
92	Cyst Fluid Analysis in Pancreatic Intraductal Papillary Mucinous Neoplasms. Clinical Cancer Research, 2016, 22, 4966-4967.	6.8	5
93	Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 523-532.	2.9	78
94	Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer. Practical Radiation Oncology, 2016, 6, 417-424.	2.7	25
95	Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Reports, 2016, 17, 2445-2459.	6.3	558
96	Pancreatic cancer biology and genetics from an evolutionary perspective. Nature Reviews Cancer, 2016, 16, 553-565.	60.8	369
97	Metastatic progression is associated with dynamic changes in the local microenvironment. Nature Communications, 2016, 7, .	13.7	118
98	IGFBP-3 Gene Methylation in Primary Tumor Predicts Recurrence of Stage II Colorectal Cancers. Annals of Surgery, 2016, 263, 337-344.	4.6	24
99	The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes. Modern Pathology, 2016, 29, 1058-1069.	4.8	100
100	Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531, 47-52.	37.9	3,324
101	Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opinion on Therapeutic Targets, 2016, 20, 341-359.	3.7	37
102	Transflip mutations produce deletions in pancreatic cancer. Genes Chromosomes and Cancer, 2015, 54, 472-481.	3.0	10
103	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	37.9	2,465
104	Are We Systematically Under-Dosing Patients With Fluorouracil?. Journal of Clinical Oncology, 2015, 33, e36-e37.	16.9	8
105	Semaphorin 3D autocrine signaling mediates the metastatic role of annexin A2 in pancreatic cancer. Science Signaling, 2015, 8, .	5.4	110
106	Phase 2 multiâ€institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer, 2015, 121, 1128-1137.	4.0	506
107	Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Nature Medicine, 2015, 21, 1060-1064.	33.0	146
108	Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. Genome Research, 2015, 25, 1536-1545.	4.6	136

#	Article	IF	Citations
109	A Quantitative System for Studying Metastasis Using Transparent Zebrafish. Cancer Research, 2015, 75, 4272-4282.	3.8	130
110	Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics, 2015, 47, 1168-1178.	25.2	1,955
111	MUC1 Promoterâ€“Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer. Molecular Cancer Research, 2015, 13, 439-448.	3.1	18
112	Processed pseudogenes acquired somatically during cancer development. Nature Communications, 2014, 5, .	13.7	103
113	CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. Epigenetics, 2014, 9, 738-746.	3.0	7
114	The Tumor Suppressorrpl36Restrains KRAS^{G12V}-Induced Pancreatic Cancer. Zebrafish, 2014, 11, 551-559.	1.4	26
115	dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer. Cancer Biology and Therapy, 2014, 15, 688-698.	4.1	40
116	Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival. Clinical Cancer Research, 2014, 20, 6200-6211.	6.8	42
117	Autophagy, p53, and Pancreatic Cancer. New England Journal of Medicine, 2014, 370, 1352-1353.	34.6	38
118	The association between circulating high-sensitivity C-reactive protein concentration and pathologic measures of colonic inflammation. Cancer Causes and Control, 2014, 25, 409-418.	1.7	10
119	Long Interspersed Element-1 Protein Expression Is a Hallmark of Many Human Cancers. American Journal of Pathology, 2014, 184, 1280-1286.	3.4	334
120	A draft map of the human proteome. Nature, 2014, 509, 575-581.	37.9	2,162
121	Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative Proteomics. Molecular and Cellular Proteomics, 2014, 13, 2803-2811.	3.0	56
122	Hypersensitivities for Acetaldehyde and Other Agents among Cancer Cells Null for Clinically Relevant Fanconi Anemia Genes. American Journal of Pathology, 2014, 184, 260-270.	3.4	13
123	Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2014, 25, 735-747.	33.0	1,874
124	Molecular pathways in pancreatic carcinogenesis. Journal of Surgical Oncology, 2013, 107, 8-14.	1.5	73
125	Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 6544-6555.	6.8	153
126	Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumorâ€“vessel relationships. Journal of Radiation Oncology, 2013, 2, 413-425.	0.4	78

#	Article	IF	Citations
127	Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Medicine, 2013, 5, 26.	9.6	19
128	KRAS G>A mutation favors poor tumor differentiation but may not be associated with prognosis in patients with curatively resected duodenal adenocarcinoma. International Journal of Cancer, 2013, 132, 2502-2509.	4.3	13
129	FAM190A Deficiency Creates a Cell Division Defect. American Journal of Pathology, 2013, 183, 296-303.	3.4	29
130	Correlation of Smad4 Status With Outcomes in Patients Receiving Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy After Resection for Pancreatic Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2013, 87, 458-459.	1.5	22
131	RhoC Interacts with Integrin Î±5Î²1 and Enhances Its Trafficking in Migrating Pancreatic Carcinoma Cells. PLoS ONE, 2013, 8, e81575.	2.3	21
132	Clinicopathologic and Genetic Characterization of Traditional Serrated Adenomas of the Colon. American Journal of Clinical Pathology, 2012, 138, 356-366.	0.7	62
133	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 2012, 486, 266-270.	37.9	317
134	CpG Island Methylator Phenotypeâ€“Positive Tumors in the Absence ofMLH1Methylation Constitute a Distinct Subset of Duodenal Adenocarcinomas and Are Associated with Poor Prognosis. Clinical Cancer Research, 2012, 18, 4743-4752.	6.8	49
135	Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut, 2012, 61, 1085-1094.	16.8	142
136	Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors. American Journal of Surgical Pathology, 2012, 36, 173-184.	3.5	520
137	Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors. Clinical Cancer Research, 2012, 18, 6339-6347.	6.8	254
138	A new branch on the tree: Next-generation sequencing in the study of cancer evolution. Seminars in Cell and Developmental Biology, 2012, 23, 237-242.	5.4	34
139	Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies. Cell, 2012, 148, 362-375.	33.7	396
140	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 2012, 491, 399-405.	37.9	1,915
141	Sessile serrated adenomas: high-risk lesions?. Human Pathology, 2012, 43, 1808-1814.	2.3	25
142	Personalized Medicine in Pancreatic Cancer: Prognosis and Potential Implications for Therapy. Journal of Gastrointestinal Surgery, 2012, 16, 1651-1652.	1.7	3
143	HMGA1 Induces Intestinal Polyposis in Transgenic Mice and Drives Tumor Progression and Stem Cell Properties in Colon Cancer Cells. PLoS ONE, 2012, 7, e30034.	2.3	98
144	Genetically Defined Subsets of Human Pancreatic Cancer Show Unique In Vitro Chemosensitivity. Clinical Cancer Research, 2012, 18, 6519-6530.	6.8	66

#	Article	IF	Citations
145	DNA methylation biomarker candidates for early detection of colon cancer. Tumor Biology, 2012, 33, 363-372.	1.2	64
146	Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts. Journal of Gastrointestinal Surgery, 2012, 17, 339-344.	1.7	61
147	Prevalence of the Alternative Lengthening of Telomeres Telomere Maintenance Mechanism in Human Cancer Subtypes. American Journal of Pathology, 2011, 179, 1608-1615.	3.4	499
148	Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development. Cell, 2011, 144, 27-40.	33.7	2,267
149	AGR2 Is a Novel Surface Antigen That Promotes the Dissemination of Pancreatic Cancer Cells through Regulation of Cathepsins B and D. Cancer Research, 2011, 71, 7091-7102.	3.8	139
150	Establishment and Characterization of a New Cell Line, A99, From a Primary Small Cell Carcinoma of the Pancreas. Pancreas, 2011, 40, 905-910.	0.9	22
151	Histologic Variations in Juvenile Polyp Phenotype Correlate With Genetic Defect Underlying Juvenile Polyposis. American Journal of Surgical Pathology, 2011, 35, 530-536.	3.5	40
152	Sessile serrated adenomas and classical adenomas: An epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract. International Journal of Cancer, 2011, 129, 1889-1898.	4.3	53
153	Genomic and Epigenomic Integration Identifies a Prognostic Signature in Colon Cancer. Clinical Cancer Research, 2011, 17, 1535-1545.	6.8	144
154	Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology, 2011, 24, 1237-1247.	4.8	94
155	GATA6 Activates Wnt Signaling in Pancreatic Cancer by Negatively Regulating the Wnt Antagonist Dickkopf-1. PLoS ONE, 2011, 6, e22129.	2.3	92
156	Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the Pancreas. Annals of Surgery, 2010, 251, 470-476.	4.6	220
157	Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature, 2010, 464, 610-614.	37.9	494
158	The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 2010, 467, 1109-1113.	37.9	1,261
159	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 2010, 467, 1114-1117.	37.9	2,329
160	Cross-platform Comparison of Two Pancreatic Cancer Phenotypes. Cancer Informatics, 2010, 9, CIN.S5755.	1.9	1
161	A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma. PLoS Medicine, 2010, 7, e1000307.	8.1	217
162	Cronkhite-Canada Syndrome: Gastric Involvement Diagnosed by MDCT. Case Reports in Medicine, 2009, 2009, 1-4.	0.7	11

#	Article	IF	Citations
163	Downregulation of sodium transporters and NHERF proteins in IBD patients and mouse colitis models: Potential contributors to IBD-associated diarrhea. Inflammatory Bowel Diseases, 2009, 15, 261-274.	2.9	118
164	Epigenetic Changes in Cancer. Annual Review of Pathology: Mechanisms of Disease, 2009, 4, 229-249.	30.6	157
165	Increased Cyclooxygenase-2 Expression in Juvenile Polyposis Syndrome. Clinical Gastroenterology and Hepatology, 2009, 7, 93-97.	6.0	15
166	Beta-catenin Nuclear Labeling is a Common Feature of Sessile Serrated Adenomas and Correlates With Early Neoplastic Progression After BRAF Activation. American Journal of Surgical Pathology, 2009, 33, 1823-1832.	3.5	103
167	HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Modern Pathology, 2009, 23, 98-104.	4.8	80
168	The Pathology and Genetics of Metastatic Pancreatic Cancer. Archives of Pathology and Laboratory Medicine, 2009, 133, 413-422.	2.4	209
169	Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Research, 2008, 10, .	4.8	28
170	Occurrence of Colorectal Adenomas in Younger Adults: An Epidemiologic Necropsy Study. Clinical Gastroenterology and Hepatology, 2008, 6, 1011-1015.	6.0	66
171	Frequent genomic copy number gain and overexpression of GATA-6 in pancreatic carcinoma. Cancer Biology and Therapy, 2008, 7, 1593-1601.	4.1	68
172	Copy number alterations in pancreatic cancer identify recurrentPAK4amplification. Cancer Biology and Therapy, 2008, 7, 1793-1802.	4.1	123
173	Frequent Î²-Catenin Nuclear Labeling in Sessile Serrated Polyps of the Colorectum With Neoplastic Potential. American Journal of Clinical Pathology, 2008, 129, 416-423.	0.7	47
174	HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Modern Pathology, 2008, 22, 43-49.	4.8	100
175	Enhanced sensitivity to IGF-II signaling links loss of imprinting ofIGF2to increased cell proliferation and tumor risk. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20926-20931.	7.5	98
176	Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types. Cancer Biology and Therapy, 2007, 6, 1546-1552.	4.1	34
177	Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2007, 25, 319-325.	16.9	383
178	Aberrant methylation ofReprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer, 2006, 107, 251-257.	4.0	48
179	When should one subtract background fluorescence in 2-color microarrays?. Biostatistics, 2006, 8, 695-707.	2.1	23
180	Identifying Allelic Loss and Homozygous Deletions in Pancreatic Cancer without Matched Normals Using High-Density Single-Nucleotide Polymorphism Arrays. Cancer Research, 2006, 66, 7920-7928.	3.8	79

#	Article	IF	Citations
181	Sessile Serrated Adenomas With Low- and High-Grade Dysplasia and Early Carcinomas. American Journal of Clinical Pathology, 2006, 126, 564-571.	0.7	164
182	Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clinical and Experimental Metastasis, 2006, 23, 357-365.	2.6	58
183	RPL38, FOSL1, and UPP1 Are Predominantly Expressed in the Pancreatic Ductal Epithelium. Pancreas, 2005, 30, 158-167.	0.9	32
184	Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biology and Therapy, 2005, 4, 1381-1386.	4.1	36
185	Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biology and Therapy, 2005, 4, 548-554.	4.1	142
186	Stromal responses to carcinomas of the pancreas: Juxtatumoral gene expression conforms to the infiltrating pattern and not the biologic subtype. Cancer Biology and Therapy, 2005, 4, 302-307.	4.1	36
187	Pancreaticobiliary Cancers With Deficient Methylenetetrahydrofolate Reductase Genotypes. Clinical Gastroenterology and Hepatology, 2005, 3, 752-760.	6.0	40
188	Claudin 4 Protein Expression in Primary and Metastatic Pancreatic Cancer. American Journal of Clinical Pathology, 2004, 121, 226-230.	0.7	152
189	Cathepsin D protein levels in colorectal tumors: Divergent expression patterns suggest complex regulation and function. International Journal of Oncology, 2004, , .	3.8	2
190	Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biology and Therapy, 2004, 3, 651-656.	4.1	35
191	Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2004, 164, 903-914.	3.4	197
192	Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Human Pathology, 2004, 35, 357-366.	2.3	138
193	Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene, 2004, 24, 850-858.	6.5	155
194	Notch mediates TGFÎ±-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell, 2003, 3, 565-576.	33.0	638
195	Multicomponent Analysis of the Pancreatic Adenocarcinoma Progression Model Using a Pancreatic Intraepithelial Neoplasia Tissue Microarray. Modern Pathology, 2003, 16, 902-912.	4.8	382
196	Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays. American Journal of Pathology, 2003, 162, 1151-1162.	3.4	463
197	Gene Expression in Neoplasms of the Pancreas: Applications to Diagnostic Pathology. Advances in Anatomic Pathology, 2003, 10, 125-134.	2.3	13
198	Results of Pancreaticoduodenectomy for Lymphoplasmacytic Sclerosing Pancreatitis. Annals of Surgery, 2003, 237, 853-859.	4.6	190

#	Article	IF	Citations
199	Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology. American Journal of Pathology, 2002, 160, 1239-1249.	3.4	275
200	Exploring the Host Desmoplastic Response to Pancreatic Carcinoma. American Journal of Pathology, 2002, 160, 91-99.	3.4	189
201	Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology, 2002, 123, 365-372.	0.9	131
202	Reed-Sternberg-like cells in lymph node aspirates in the absence of Hodgkin's disease: Pathologic significance and differential diagnosis. Diagnostic Cytopathology, 2002, 27, 335-339.	1.1	26
203	Pancreatic cancer. Current Problems in Cancer, 2002, 26, 176-275.	2.0	270
204	Colloid Carcinomas of the Pancreas and Periampullary Region. American Journal of Surgical Pathology, 2002, 26, 952-953.	3.5	3
205	STK11/LKB1 Peutz-Jeghers Gene Inactivation in Intraductal Papillary-Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2001, 159, 2017-2022.	3.4	261
206	Colchicine Toxicity. American Journal of Surgical Pathology, 2001, 25, 1067-1073.	3.5	159
207	Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Increasingly Recognized Clinicopathologic Entity. Annals of Surgery, 2001, 234, 313-322.	4.6	291
208	Dpc4 Protein in Mucinous Cystic Neoplasms of the Pancreas. American Journal of Surgical Pathology, 2000, 24, 1544-1548.	3.5	167
209	Dpc-4 Protein Is Expressed in Virtually All Human Intraductal Papillary Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2000, 157, 755-761.	3.4	252
210	Elevations in Cathepsin B Protein Content and Enzyme Activity Occur Independently of Glycosylation during Colorectal Tumor Progression. Journal of Biological Chemistry, 1997, 272, 29190-29199.	2.2	48
211	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 0, , 1-13.	2.3	43
212	Title is missing!. , 0, .		2
213	Title is missing!. , 0, .		1
214	A microglia clonal inflammatory disorder in Alzheimerâ€™s disease. ELife, 0, 13, .	1.6	5
215	Syndecan-1 Is a Key Mediator of Entosis and Cellular Competition in Pancreatic Cancer. Pancreas, 0, 55, e227-e235.	0.9	0
216	SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence. Nature Cancer, 0, 6, 1839-1856.	22.5	3

#	Article	IF	Citations
217	Safety and Feasibility of Intra-Arterial Treatment of Pancreatic Cancer Using an Emulsion of Ethiodized Oil plus Bumetanide in an Oncopig Model. Journal of Vascular and Interventional Radiology, 0, 37, 107908.	1.1	0
218	Genomic evolution of pancreatic cancer at single-cell resolution. Nature Genetics, 0, , .	25.2	0